Vitamin D treatment for connective tissue diseases: hope beyond the hype?

Research output: Contribution to journalReview articlepeer-review


Colleges, School and Institutes

External organisations

  • University of Manchester


The prevalence of vitamin D deficiency is increased among patients with CTDs. The active form of vitamin D (calcitriol) is a potent regulator of the immune system and may suppress inflammatory responses. This has led to claims that vitamin D may be a safe treatment, or a treatment adjunct, to reduce systemic inflammation in this patient population. It is important to note, however, that there is insufficient evidence from robust clinical trials to support these novel uses for vitamin D. In this review we examine the potential role of vitamin D as a treatment adjunct for CTDs. We will discuss how vitamin D may modulate the immune response and review the current evidence for using vitamin D to treat CTDs and their associated co-morbidities. We conclude that while there is much excitement about vitamin D in this context, further well-designed trials are needed to demonstrate its efficacy in the treatment of patients with CTDs.


Original languageEnglish
Pages (from-to)178-186
Number of pages9
JournalRheumatology (Oxford, England)
Issue number2
Early online date13 May 2016
Publication statusPublished - 1 Feb 2017


  • cardiovascular disease, connective tissue disease, inflammation, systemic lupus erythematosus, vitamin D

ASJC Scopus subject areas

Sustainable Development Goals